teaser
Novartis will showcase more than 160 presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and haematological diseases.
The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held from December 6-10, will feature data presentations from Phase III studies of Afinitor
